- This topic has 1 voice and 0 replies.
Viewing 0 reply threads
-
Posts
-
-
Scottish patients with pulmonary arterial hypertension (PAH) can now be treated with Actelion‘s Uptravi (selexipag) through the country’s National Health System (NHS) after a positive recommendation from the Scottish Medicines Consortium (SMC). However, the use of this therapy will be restricted to adult patients in WHO functional class 3 whose symptoms are not manageable or do not tolerate other available PAH therapies.
Read more about this story here: Scottish Agency Recommends Uptravi for PAH Treatment Through National Health System
Have you heard of selexipag? What do you think of this news?
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
